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The beta-airu.rgir receptor system in the heart. Evi- 
dence for the activation ot the sympaIhetic ncrvou~ system 
at rest and during exercise in patients with congestive hew 
failure was reported aimosl 30 years ago (II. In 1975. 
Thomas and Marks (2) noted a comlaIiun of circulating 
catecholamine levels with rhe degree of hean failure and 
speculated abour rhe powxial deleterious effects of elevated 
norepinephrine isvels on the responsweness of the mycar- 
dial beta-adrenergic receptor. Bristow et nl. (3) wbsequcndy 
showed that a decrease in beta-receptor density in failmg 
human hearIs leads m subsensilivily of the bewadrenergic 
pathway and decreased muscle contrxiion with the beta- 
agonist isoproterenol. Four years larer. Fowlei et al. (41 
demonstrared that myocardial beta-adrenergic down- 
regulation began even in mild 10 moderate vemricular drs- 
function and was pharmacologically specific for heft- 
agonist-dependent augmenta:ion of comracrihty. By 19X8. a 
further order of complexity of the myocardial beta- 
adrenergic receptor syslem was well established (5.6). II 
became clear that both beta,- and beta,-adrenoceprors co- 
exist in Ihe human heart: stimulation of both subtypes 
contributes to the inotmpic effects of beta-adrenergic ago- 
nists through coupling to adenylare cyclase. Moreover. 
insights were made (71 into Ihe role of fhe proteins thar 
couple the signal generated by agonist occupancy of a 
receptor to the activation of the second messenger effector. 
adenylale cydare. Because these guanine nucleolide binding 
regulatory proteins, or C prowins. vary somewhat in swum- 
ture. they may be either slim&tory or inhibitury in &on. 
Pathophysinlogic consequences of sympathetic nervous sys- 
tern activation in eangestive heart failure. There are not 
confined to the myocardlal beta-reccplor. Cchn et al. 18) 
reported that circulating levels of norepinephrine were di- 
rectly related to mofiality in patients with hean Failure and 
tha! norepinephrine was the single univariate predictor that 
independently corrrlaIed with morlrlity risk. Simons and 
Doaning (91 dexnbed animal models tn which norepinzph- 
nnc infwion induced surtamrd coronary usocunsIriction 
Gth :ewltanl myocardial hber n&x&. myofihnllardegen- 
eratlon and mononuclear leukwytic infiltration. These cf- 
fecrs could be prevented by alpha-adrenergic blockade 
rather than hewadrenergic blockade. More recenlly Iwo 
large mulricen:er inrervendon ni& (IO.1 II studying a hctcr- 
ogen;ous population of patients wirh congestive hea< failure 
confij-med the prognostic m~portnnce of neurocndocrine 
function and cardiovascular homeostasis. A subset of pa- 
tient\ uilh leti venrricular dysfunction but no overt signs of 
congestive hean failure were compared wah comrol subjects 
and pakntr t~lth overt fadurc m Ihe Studies of Lcfi Ven- 
Iricula: Dysfmwion ISOLVD) trial (101. There was a highly 
Ggntficanl increase m ploTma norepinephrine in Ihe a5?mp- 
torn&- paticnl\ as cumpared with levels in comrol subjects. 
Norepmephrme v&r< were significantly higher still m ihe 
\ymptomatlc patients with left ventricular dysfuncrion. In 
rhe CONSENSUS trial II Ii. patients with severe heart 
failure symploms and cardiac dysfunction were waled wilh 
enalaprd or placebo. A s@nificanl posliive relatton heween 
mondiir) snd norcpmephriw levels was demonstrmed in the 
phcchu group but nv1 among patient> treated with enalspril. 
Other invrstieators 121 as well have provided some hope 
that drug wervenlil may modify Ihe adverse effects of 
neuroendocrme activation in congestive heart failure. 
Beta.adrenergie receptor blockade in congestive hear1 fail. 
me: the present study. Bewrecepror blo:kers have been 
shown to reduce lotal mortality and the incidence of sudden 
dealb in pahentr with congestive heart failure nfier an acme 
myocardlal infarcIion 113.141. And as early as l97j Waag- 
stein et al. t 15) from the Universily of GMeborg. Snedcn 
were the Iirsr m propose rhe use of loae-lerm bera-adrenergic 
recepror blockade in chronic congestwe cardiomyopathy lo 
alleviate \)mptoms and improve cardiac function. Their 
picwzering aurk was followed by their own later rcpons and 
those of others C 16-2). culminaring in the most recent 
article puhliqhed in Ihis issue of rhe Journal (23). As outlined 
in Table I. a large majoriry of investigators have shown 
clmical and hemodynamic improvemenl with the beI+ 
blockers. Heart rate and filling pressures decrease, whereas 
cjcctlon fraction. systemic pressure and exercise capacily 
increase. The potential mechanisms whereby these rome- 
times impressive results are obIained are suggested by the 
present investigat.,rs (23) and have been reviewed exten- 
bively m the pasl(?4-26). 
Unanswered qoeslions. Unfnrtunalely. questions rai5ed 
by Ihe oripmal description of the treatment still remam 
unanswered. 
1, Which hrrn-ndrenwxir hbwbinp drtrp .shotdd be used? 
Yost of the studies have used meroprolol, a drug a’ith 
r&live beIa,-receptor selectivity and no agonist aclwly. 
However. other drugs have aiso been effective (16.18). 
Moreover, m hypertension. vanous beta-blockmg agents 
had divcrsc efkcts on peripheral vascular resismnce. cardiac 
oulpu~. renal blood flow and beta-adrenaceplor density. yet 
all lowered blood pressure to the same degree (271. 
2. ffu~v lona rnrrrt GIEI.UP? he ~#rn hciore a clinical r~srrlr 
i.s nh.~wd~ In the studies reviewed (16-23). the duration of 
treannent varied from 8 weeks to 1.5 years. In the present 
sludy f23). the investigators chose lo reassess certain pa- 
tients if clinical improvement war noted after 6 months. and 
thtisc pAen&’ data are included with data from patienls 
evaluated earlier. It is not clear when a therapeutic trial of 
beta-blockers should be abandoned. 
3. Huw rnuny pritients arc ~nnbfc 10 rnlrrrrlf Iherap_v or 
shon, 110 be~~fir? These dala are extremely hard lo glean 
from the published studies and Table I reflects my interpre- 
tation of the reported results. Moreover. in the U.S., the 
smallest tablets of metoprolal available are SO mg. 50 that Ihe 
initiatfon of 5 mg doses, as in Sweden. is technically com- 
plex. Waagstein et al. (IS) wggesl that there is lruly an inilial 
period of treatment when the patient may feel worse with 
metoprolol than at baseline. It will be important to delineate 
Ihe expected duration of this pel,iod in future studies. 
4. Cntr pnlieau will! idwnic, ns WPJI OS idinpnrhit, 
dhw’ cordiornyoprrlhq. h&it ,fnm hem-h/or&R drags? 
The presem invesligalors (231 ailempled IO answer this 
question and showed a disappointing lack of benefit in the 
patients with inchemic cardiomyopalhy, but the numbers 
were too small for statistical compariron. Some data (28) 
suggest that alteralion of the inhibhory G proteins may differ 
in failing hearts with ischemic versus idiopalhic dilated 
cardiomyopathy. This difference has some functional rele- 
vance to inotroplc responsiveness to endogenous catechol- 
amine% Conceivably, it may influence the response to beta- 
adrcncrgic blockade as well. Nevertheless, beta-blockers 
continue IO bc very effective in patients with ischemic heart 
disease studied after myocardial infarclion (13,14.?9). 
Conclusions. The present report by Anderrson et al. (231 
is clearly a welcome confirmation of lheir evlier work. 
Results of ongoing studies of the use of metoprolol in 
idiopathic dilated cardiomyopalhy are eagerly awaited. The 
issues of which patients should be treated wilh beta-blockers 
and for how long and with which drug need to be addressed 
in the future. 
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